Abstract LB293: The evolution of MRD assays: Moving beyond the tumor-Informed bespoke NGS panel
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb293
Abstract: The non-invasive detection of circulating tumor DNA (ctDNA) from plasma has been shown to have clinical value for detection of minimal residual disease (MRD), identification of emerging resistance to treatment, and predicting treatment response. The… read more here.
Keywords: tumor informed; panel; mrd; informed bespoke ... See more keywords